Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
100 hedge funds and large institutions have $150M invested in Bellicum Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 28 reducing their positions, and 8 closing their positions.
200% more call options, than puts
Call options by funds: $942K | Put options by funds: $314K
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
11% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 28
4% more funds holding
Funds holding: 96 → 100 (+4)
21% less capital invested
Capital invested by funds: $189M → $150M (-$39.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.16M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$2.07M |
| 3 |
JP Morgan Chase
New York
|
+$2.04M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$925K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$677K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$9.58M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.49M |
| 3 |
Millennium Management
New York
|
-$864K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$709K |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$690K |
BLCM Hedge Fund Activity: Q3 2018 in Review
100 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q3 2018, worth a combined $150M — down 21% from $189M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new BLCM positions and 8 closed out — a net gain of 4 holders — while 31 added to existing stakes and 28 trimmed.
The largest buyer was BlackRock, adding an estimated $2.16M. The largest seller was Baker Bros. Advisors, cutting an estimated $9.58M.
- 100 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q3 2018, up from 96 in Q2 2018.
- Funds reported $150M of Bellicum Pharmaceuticals, Inc. stock for Q3 2018, down 21% quarter-over-quarter.
- 12 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q3 2018 and 8 closed out, a net change of +4 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q3 2018 was BlackRock, an estimated $2.16M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q3 2018 was Baker Bros. Advisors, an estimated $9.58M sold.
Based on aggregated 13F filings for Q3 2018.